
Federal panel to review proposal for first human CRISPR test
pharmafile | June 20, 2016 | News story | Research and Development, Sales and Marketing | crispr, gene editing, human testing, oncology
A US Federal safety board is set to review a proposal for the first human use of the gene editing technology, CRISPR, which will target myeloma, melanoma and sarcomas, according to the National Institutes of Health (NIH).
The Recombinant DNA Advisory committee (RAC) will look at using the type of molecular scissors which are able to precisely cut DNA, where the patient’s own blood cells will be removed and genetically altered using the technology.
Submitted by a team from the University of Pennsylvania, the researchers could be granted a head start on other players in the CRISPR space, such as Editas Medicines and Intellia Therapeutics if approved.
In a blog post on the NIH website, associate director for science policy, Carrie D. Wolinetz, says: “Researchers in the field of gene transfer are excited by the potential of utilising CRISPR/Cas9 to repair or delete mutations that are involved in numerous human diseases in less time and at a lower cost than earlier gene editing systems.”
However, she welcomes that, since there are significant scientific, safety and ethical implications involved with this treatment, that RAC will discuss these issues in a public forum ensuring that “innovations in biomedical research” are supported “in a fashion that reflects well-established scientific and ethical principles.”
A decision on whether to approve CRISPR for human testing is expected during the committee meeting taking place June 21/22.
Sean Murray
Related Content

START and Rome cancer institute partner to expand early-phase trial access in Italy
The START Center for Cancer Research is partnering with Rome-based Istituti Fisioterapici Ospitalieri (IFO) to …

Highlighting the value of lab research for healthcare innovation
Diagnostic innovation and patient safety have dominated this year’s healthcare-focussed awards to mark European Laboratory …

Charity commits £800,000 to AI research into late breast cancer recurrence
Breast Cancer Now is investing £800,000 in two research projects using artificial intelligence to investigate …





